Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer - read this article along with other careers information, tips and advice on BioSpace
CHICAGO, IL and FORT WORTH, TX (PRWEB) October 28, 2021 Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced